Canada Markets closed

Janux Therapeutics, Inc. (JANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.41-0.65 (-5.88%)
At close: 04:00PM EDT
10.41 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Loading interactive chart...
  • Business Wire

    Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

    SAN DIEGO, May 10, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

  • Business Wire

    Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

    SAN DIEGO, April 26, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), in separate poster presentations at the 18th A

  • Business Wire

    Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

    SAN DIEGO, March 18, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.